Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck × Interleukin-2 × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT05902520 2026-01-08

ACT

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Lung Neoplasms, Melanoma, Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

NCT06236425 2026-01-08

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Phase 1 Active not recruiting

7 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04596033 2022-07-15

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Phase 1 Terminated

49 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT00006033 2013-05-30

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

Phase 2 Completed

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Clinical Trials

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

ACT

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer